"http://www.vhebron.net/es/" Vall d’Hebron University Hospital has participated in an international study, published in the " "http://www.nejm.org/doi/full/10.1056/NEJMoa1309748" New England Journal of Medicine, which has demonstrated that the addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent or metastatic cervical cancer improves the overall survival and reduces by 30% the risk of dying from this disease. The hospital and the "http://www.vhio.net/" Vall d’Hebron Institute of Oncology are, together with other Spanish Centers from the GEICO (the Spanish network of research in ovarian Cancer), the only European participants of the international phase III clinical trial which has used a combination of chemotherapy and bevacizumab, which is an antibody administered to manage cancer because it inhibits the tumor growth and prevents the formation of new blood vessels from the preexisting ones. Up to date, when the initial treatment failed in these patients (surgery in early stages and a combination of chemotherapy and radiotherapy for advanced stages), the only therapeutic option was the conventional chemotherapy, which had an overall survival of one year. The study was carried out in 452 patients with cervical cancer from 164 American and Spanish hospitals. All the patients had previously received the standard treatment, but the cancer remained or had just reappeared. With the combination of bevacizumab and chemotherapy, the average survival improved in nearly 4 months and reduced by the 30% the risk of dying from this cancer. Dr. Ana Oaknin, oncologist specialized in gynecology tumors at Vall d’Hebron, explained that “before the beginning of the clinical trial in 2009, it was very difficult that these patients could live more than one year, but now their survival has improved to the 17 months, preserving their quality of life”. “It seems a little step, but it is very important because this cancer mainly affects young women, aged between 30 and 40, who use to have a strong family environment”, reported Dr. Oaknin. Vall d’Hebron University Hospital treats every year nearly 25 women with advanced cervical cancer, and is the reference center in Spain for this disease.